智通财经APP获悉，康宁杰瑞制药-B(09966)涨超4%，截至发稿，涨4.08%，报3.57港元，成交额1834万港元。
消息面上，康宁杰瑞制药近期宣布，HER2双特异性抗体偶联药物（ADC）JSKN003获国家药品监督管理局（NMPA）药品审评中心（CDE）同意开展一项Ⅲ期临床研究（研究编号：JSKN003-306），用于对比研究者选择化疗治疗铂耐药复发性上皮性卵巢癌、原发性腹膜癌或输卵管癌。
中泰证券表示，公司拥有领先in-house技术平台，持续迭代，包括单域抗体平台、双抗平台、糖基定点偶联平台（ADC）、皮下给药高浓度制剂平台和最新开发的双毒素ADC平台。已有多个产品处于商业化和注册临床阶段。该行指，与目前公司市值相比，康宁杰瑞制药处于相对低估的水平，首予“增持”评级。东吴证券则指出，公司是国内技术领先企业，差异化管线布局逐渐进入收获期，看好公司未来长期发展，首予“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.